On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications
暂无分享,去创建一个
Robert Day | R. Day | Frédéric Couture | François D'Anjou | Frédéric Couture | François D'Anjou | F. Couture
[1] N. Seidah,et al. The isoforms of proprotein convertase PC5 are sorted to different subcellular compartments , 1996, The Journal of cell biology.
[2] G. Salvesen,et al. Emerging principles in protease-based drug discovery , 2010, Nature Reviews Drug Discovery.
[3] Nikolaj Blom,et al. Prediction of proprotein convertase cleavage sites. , 2004, Protein engineering, design & selection : PEDS.
[4] D. Griggs,et al. Proprotein convertase activation of aggrecanases in cartilage in situ. , 2008, Archives of biochemistry and biophysics.
[5] C. Van Noorden,et al. Antiprotease therapy in cancer: hot or not? , 2006, Expert opinion on biological therapy.
[6] T. Watanabe,et al. Arg-X-Lys/Arg-Arg motif as a signal for precursor cleavage catalyzed by furin within the constitutive secretory pathway. , 1991, The Journal of biological chemistry.
[7] J. Reichert,et al. Development trends for human monoclonal antibody therapeutics , 2010, Nature Reviews Drug Discovery.
[8] Jianhua Wu,et al. FurinDB: A Database of 20-Residue Furin Cleavage Site Motifs, Substrates and Their Associated Drugs , 2011, International journal of molecular sciences.
[9] A. Prat,et al. The Proprotein Convertase PCSK9 Induces the Degradation of Low Density Lipoprotein Receptor (LDLR) and Its Closest Family Members VLDLR and ApoER2* , 2008, Journal of Biological Chemistry.
[10] H. Ma,et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis , 2005, Nature.
[11] A. Godwin,et al. Increased Expression of the Pro-Protein Convertase Furin Predicts Decreased Survival in Ovarian Cancer , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.
[12] C. Boileau,et al. Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents , 2010, Expert opinion on therapeutic patents.
[13] Jeffrey W. Smith,et al. Targeting Host Cell Furin Proprotein Convertases as a Therapeutic Strategy against Bacterial Toxins and Viral Pathogens* , 2007, Journal of Biological Chemistry.
[14] Piotr Cieplak,et al. Substrate Cleavage Analysis of Furin and Related Proprotein Convertases , 2008, Journal of Biological Chemistry.
[15] S. Zucker,et al. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment , 2000, Oncogene.
[16] N. Seidah,et al. Inhibition of Chikungunya Virus Infection in Cultured Human Muscle Cells by Furin Inhibitors , 2008, Journal of Biological Chemistry.
[17] Y. Maeda,et al. The acidic environment of the Golgi is critical for glycosylation and transport. , 2010, Methods in enzymology.
[18] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[19] A. Prat,et al. The proprotein convertases and their implication in sterol and/or lipid metabolism , 2006, Biological chemistry.
[20] I. Lindberg,et al. Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics. , 2010, Journal of medicinal chemistry.
[21] D. Lowy,et al. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[22] A. Prat,et al. The proprotein convertases are potential targets in the treatment of dyslipidemia , 2007, Journal of Molecular Medicine.
[23] B. Ross,et al. Identification of inhibitors using a cell-based assay for monitoring Golgi-resident protease activity. , 2007, Analytical biochemistry.
[24] N. Seidah,et al. The Influence of PCSK9 Polymorphisms on Serum Low-Density Lipoprotein Cholesterol and Risk of Atherosclerosis , 2010, Current atherosclerosis reports.
[25] R. Day,et al. Cutting back on pro-protein convertases: the latest approaches to pharmacological inhibition , 2005, Trends in Pharmacological Sciences.
[26] P. Espenshade,et al. Molecular identification of the sterol-regulated luminal protease that cleaves SREBPs and controls lipid composition of animal cells. , 1998, Molecular cell.
[27] T. Komiyama,et al. Furin Inhibition by Compounds of Copper and Zinc* , 2004, Journal of Biological Chemistry.
[28] J. A. Hobden,et al. Nona-D-Arginine Amide for Prophylaxis and Treatment of Experimental Pseudomonas aeruginosa Keratitis , 2010, Current eye research.
[29] Benoît Cadieux,et al. Molecular cloning and embryonic expression of zebrafish PCSK5 co‐orthologues: Functional assessment during lateral line development , 2010, Developmental dynamics : an official publication of the American Association of Anatomists.
[30] N. Seidah,et al. Cell-surface processing of extracellular human immunodeficiency virus type 1 Vpr by proprotein convertases. , 2008, Virology.
[31] C. Brenner,et al. The synthesis of inhibitors for processing proteinases and their action on the Kex2 proteinase of yeast. , 1993, The Biochemical journal.
[32] A. Strongin,et al. Selective and potent furin inhibitors protect cells from anthrax without significant toxicity. , 2010, The international journal of biochemistry & cell biology.
[33] B. Hay,et al. Aminopyrrolidineamide inhibitors of site-1 protease. , 2007, Bioorganic & medicinal chemistry letters.
[34] N. Seidah,et al. Comparative cellular processing of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp160 by the mammalian subtilisin/kexin-like convertases. , 1996, The Biochemical journal.
[35] S. Millis,et al. Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine , 2006, Proceedings of the National Academy of Sciences.
[36] R. Day,et al. Inhibitors of the subtilase-like pro-protein convertases (SPCs). , 2002, Current pharmaceutical design.
[37] N. Seidah,et al. Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides 1 Published on the World Wide Web on 17 August 1999. 1 , 1999, Brain Research.
[38] N. Seidah,et al. The Proprotein Convertase (PC) PCSK9 Is Inactivated by Furin and/or PC5/6A , 2006, Journal of Biological Chemistry.
[39] I. Fournier,et al. Molecular Validation of PACE4 as a Target in Prostate Cancer. , 2011, Translational oncology.
[40] I. Wang,et al. Pharmacologic Inhibition of Site 1 Protease Activity Inhibits Sterol Regulatory Element-Binding Protein Processing and Reduces Lipogenic Enzyme Gene Expression and Lipid Synthesis in Cultured Cells and Experimental Animals , 2008, Journal of Pharmacology and Experimental Therapeutics.
[41] A. Grodzinsky,et al. Transport and equilibrium uptake of a peptide inhibitor of PACE4 into articular cartilage is dominated by electrostatic interactions. , 2010, Archives of biochemistry and biophysics.
[42] A. Roebroek,et al. Expression in human lung tumor cells of the proprotein processing enzyme PC1/PC3 Cloning and primary sequence of a 5 kb cDNA , 1992, FEBS letters.
[43] D. Szymkowski. Rational optimization of proteins as drugs: a new era of 'medicinal biology'. , 2004, Drug discovery today.
[44] R. B. Rawson. Control of lipid metabolism by regulated intramembrane proteolysis of sterol regulatory element binding proteins (SREBPs). , 2003, Biochemical Society symposium.
[45] M. Nachtigal,et al. Epigenetic regulation of proprotein convertase PACE4 gene expression in human ovarian cancer cells. , 2003, Molecular cancer research : MCR.
[46] A. Klein-Szanto,et al. Malignant conversion of non-tumorigenic murine skin keratinocytes overexpressing PACE4. , 2002, Carcinogenesis.
[47] S. O’Rahilly,et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene , 1997, Nature Genetics.
[48] F. Pinet,et al. Expression of PC2 and PC1/PC3 in human pheochromocytomas , 1994, Molecular and Cellular Endocrinology.
[49] K. Soppimath,et al. Novel delivery technologies for protein and peptide therapeutics. , 2006, Current pharmaceutical biotechnology.
[50] R. Day,et al. Proteolytic Processing of Angiopoietin-like Protein 4 by Proprotein Convertases Modulates Its Inhibitory Effects on Lipoprotein Lipase Activity* , 2011, The Journal of Biological Chemistry.
[51] A. Lauwers,et al. Limited Redundancy of the Proprotein Convertase Furin in Mouse Liver* , 2004, Journal of Biological Chemistry.
[52] G. Kundu,et al. p38 kinase is crucial for osteopontin-induced furin expression that supports cervical cancer progression. , 2010, Cancer research.
[53] N. Seidah,et al. Inhibition of proprotein convertases-1, -7 and furin by diterpines of Andrographis paniculata and their succinoyl esters. , 1999, The Biochemical journal.
[54] G. Thomas,et al. alpha1-Antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[55] Wu Jianhua,et al. Comparative study of the binding pockets of mammalian proprotein convertases and its implications for the design of specific small molecule inhibitors , 2010, International journal of biological sciences.
[56] A. Basak,et al. A Novel Enediynyl Peptide Inhibitor of Furin That Blocks Processing of proPDGF-A, B and proVEGF-C , 2009, PloS one.
[57] Yan Wang,et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates , 2009, Proceedings of the National Academy of Sciences.
[58] D. Constam,et al. Imaging proprotein convertase activities and their regulation in the implanting mouse blastocyst , 2010, The Journal of cell biology.
[59] I. Lindberg,et al. Proprotein convertase models based on the crystal structures of furin and kexin: explanation of their specificity. , 2005, Journal of molecular biology.
[60] J. Lieberman,et al. The silent treatment: siRNAs as small molecule drugs , 2006, Gene Therapy.
[61] J. Deisenhofer,et al. Molecular basis for LDL receptor recognition by PCSK9 , 2008, Proceedings of the National Academy of Sciences.
[62] C. Dubois,et al. Hypoxia enhances cancer cell invasion through relocalization of the proprotein convertase furin from the trans‐golgi network to the cell surface , 2012, Journal of cellular physiology.
[63] Mansoor M Ahmed,et al. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. , 2006, Current molecular medicine.
[64] Bonnie Peng,et al. The role of prohormone convertase‐2 in hypothalamic neuropeptide processing: a quantitative neuropeptidomic study , 2006, Journal of neurochemistry.
[65] C. Stevenson. Advances in peptide pharmaceuticals. , 2009, Current pharmaceutical biotechnology.
[66] I. Lindberg,et al. Polyarginines Are Potent Furin Inhibitors* , 2000, The Journal of Biological Chemistry.
[67] R. Leduc,et al. Subtilase-like pro-protein convertases: from molecular specificity to therapeutic applications. , 2000, Journal of molecular endocrinology.
[68] N. Seidah,et al. Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. , 2002, The American journal of pathology.
[69] D. Rader,et al. Angiopoietin-like Protein 3 Inhibits Lipoprotein Lipase Activity through Enhancing Its Cleavage by Proprotein Convertases* , 2010, The Journal of Biological Chemistry.
[70] B. Scheithauer,et al. Distribution and Regulation of Proconvertases PC1 and PC2 in Human Pituitary Adenomas , 1999, Pituitary.
[71] N. Seidah,et al. Proprotein convertases: lessons from knockouts , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[72] H. Klenk,et al. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gpl60 , 1992, Nature.
[73] H. de Haard,et al. Properties, production, and applications of camelid single-domain antibody fragments , 2007, Applied Microbiology and Biotechnology.
[74] Michele Bernasconi,et al. Furin Targeted Drug Delivery for Treatment of Rhabdomyosarcoma in a Mouse Model , 2010, PloS one.
[75] I. Lindberg,et al. Synthetic Small-Molecule Prohormone Convertase 2 Inhibitors , 2009, Molecular Pharmacology.
[76] J. A. Hobden,et al. Nona-D-arginine therapy for Pseudomonas aeruginosa keratitis. , 2009, Investigative ophthalmology & visual science.
[77] U. Reimer,et al. Translating peptides into small molecules. , 2006, Molecular bioSystems.
[78] A. Roebroek,et al. MMTV-cre-mediated fur inactivation concomitant with PLAG1 proto-oncogene activation delays salivary gland tumorigenesis in mice. , 2008, International journal of oncology.
[79] A. Prat,et al. Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation , 2009, The Journal of Biological Chemistry.
[80] R. Schneiderman,et al. Some biochemical and biophysical parameters for the study of the pathogenesis of osteoarthritis: a comparison between the processes of ageing and degeneration in human hip cartilage. , 1989, Connective tissue research.
[81] Xiaorong Zhu,et al. Analysis of peptides in prohormone convertase 1/3 null mouse brain using quantitative peptidomics , 2010, Journal of neurochemistry.
[82] Robert Langer,et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates , 2008, Proceedings of the National Academy of Sciences.
[83] W. V. D. Van de Ven,et al. Curbing activation: proprotein convertases in homeostasis and pathology , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[84] R. Day,et al. Furin Processing and Proteolytic Activation of Semliki Forest Virus , 2003, Journal of Virology.
[85] Alnawaz Rehemtulla,et al. Inhibition of Furin/Proprotein Convertase-catalyzed Surface and Intracellular Processing by Small Molecules* , 2009, The Journal of Biological Chemistry.
[86] A. Klein-Szanto,et al. PACE4 expression in mouse basal keratinocytes results in basement membrane disruption and acceleration of tumor progression. , 2005, Cancer research.
[87] A. Klein-Szanto,et al. Elevated furin expression in aggressive human head and neck tumors and tumor cell lines , 2001, Molecular carcinogenesis.
[88] S. Kunz,et al. Antiviral Activity of a Small-Molecule Inhibitor of Arenavirus Glycoprotein Processing by the Cellular Site 1 Protease , 2010, Journal of Virology.
[89] Dongqing Wei,et al. Cleavage mechanism of the H5N1 hemagglutinin by trypsin and furin , 2008, Amino Acids.
[90] M Chrétien,et al. Pro‐protein convertase gene expression in human breast cancer , 1997, International journal of cancer.
[91] R Beuscart,et al. Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. , 1990, Cancer research.
[92] N. Seidah,et al. Proprotein convertases as therapeutic targets , 2008 .
[93] H. Klenk,et al. Cleavage Activation of the Influenza Virus Hemagglutinin and Its Role in Pathogenesis , 2008 .
[94] M. O’Kennedy,et al. Biolistic mediated sorghum (Sorghum bicolor L. Moench) transformation via mannose and bialaphos based selection systems , 2010 .
[95] A. Prat,et al. Deletion of the Gene Encoding Proprotein Convertase 5/6 Causes Early Embryonic Lethality in the Mouse , 2006, Molecular and Cellular Biology.
[96] I. Lindberg,et al. The Furin Inhibitor Hexa-d-Arginine Blocks the Activation of Pseudomonas aeruginosa Exotoxin A In Vivo , 2002, Infection and Immunity.
[97] R. Leduc,et al. Inhibitory Potency and Specificity of Subtilase-like Pro-protein Convertase (SPC) Prodomains* , 2002, The Journal of Biological Chemistry.
[98] Philip Smith,et al. The localization of the insulin‐like growth factor receptor 1 (IGFR‐1) in benign and malignant breast tissue , 1997, The Journal of pathology.
[99] N. Seidah,et al. Protease inhibitors suppress in vitro growth of human small cell lung cancer , 1993, Peptides.
[100] E. Fleck,et al. Proprotein convertases regulate insulin-like growth factor 1-induced membrane-type 1 matrix metalloproteinase in VSMCs via endoproteolytic activation of the insulin-like growth factor-1 receptor. , 2004, Biochemical and biophysical research communications.
[101] A. Beck‐Sickinger,et al. Peptide drugs to target G protein-coupled receptors. , 2010, Trends in pharmacological sciences.
[102] A. Klein-Szanto,et al. Proprotein convertase inhibition results in decreased skin cell proliferation, tumorigenesis, and metastasis. , 2010, Neoplasia.
[103] J. Creemers,et al. Knock-out mouse models of proprotein convertases: unique functions or redundancy? , 2008, Frontiers in bioscience : a journal and virtual library.
[104] N. Seidah,et al. Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells. , 2008, The Journal of clinical investigation.
[105] N. Seidah. What lies ahead for the proprotein convertases? , 2011, Annals of the New York Academy of Sciences.
[106] Annik Prat,et al. The proprotein convertase PC5/6 is protective against intestinal tumorigenesis: in vivo mouse model , 2009, Molecular Cancer.
[107] N. Seidah,et al. The cysteine-rich domain of the secreted proprotein convertases PC5A and PACE4 functions as a cell surface anchor and interacts with tissue inhibitors of metalloproteinases. , 2005, Molecular biology of the cell.
[108] Vivian Hook,et al. Unique biological function of cathepsin L in secretory vesicles for biosynthesis of neuropeptides , 2010, Neuropeptides.
[109] S. Kunz,et al. Targeting the Proteolytic Processing of the Viral Glycoprotein Precursor Is a Promising Novel Antiviral Strategy against Arenaviruses , 2009, Journal of Virology.
[110] I. Lindberg,et al. Short Polybasic Peptide Sequences Are Potent Inhibitors of PC5/6 and PC7: Use of Positional Scanning-Synthetic Peptide Combinatorial Libraries as a Tool for the Optimization of Inhibitory Sequences , 2007, Molecular Pharmacology.
[111] E. Fleck,et al. Proprotein convertases furin and PC5: targeting atherosclerosis and restenosis at multiple levels , 2005, Journal of Molecular Medicine.
[112] R. Ala-aho,et al. Matrix metalloproteinases as therapeutic targets in cancer. , 2005, Current cancer drug targets.